Julie A. Vetalice, Author at ORTHOWORLD

Orthobiologics Activity Signals Collaborations and Clinical Data Essential for Company Growth

ORTHOWORLD estimates that global orthobiologic product sales account for ~10% of the orthopaedic market's revenue, overall. In 2016, that translated to just over $4.9 billion, an increase of 3% vs. 2015. For 2017 and into 2019, we're projecting similar growth.

Oct 16, 2017

The Orthopaedic Implant Company Launches an External Fixation System

ORTHOFLASH Trauma

The Orthopaedic Implant Company introduced the OIC External Fixation System.

Oct 13, 2017

Medacta Launches MiniMAX Hip Stem in U.S.

Joint Replacement ORTHOFLASH

Medacta commenced U.S. launch of the MiniMAX™ anatomical cementless hip stem.

Oct 12, 2017

NuVasive Receives Expanded FDA 510(k) Clearance for PRECICE

ORTHOFLASH Trauma

NuVasive received expanded FDA 510(k) clearance for the PRECICE® limb lengthening system.

Oct 12, 2017

DePuy Synthes Launches TFNA Augmentation System

ORTHOFLASH Trauma

DePuy Synthes commenced U.S. launch of TFNA Augmentation, which the company claims is the first PMMA cement system with specific trauma device indications.

Oct 12, 2017

DePuy Synthes Launches MAXFRAME Multi-Axial Correction System

ORTHOFLASH Robotics/Tech

DePuy Synthes is launching MAXFRAME™, a 3D simulation assisted external circular fixation device for the treatment of limb deformity in the arm, leg, foot or ankle.

Oct 11, 2017

Surgical Specialties to Distribute Ortho-ATI in Australia, New Zealand

Company Updates Competitive Landscape

Orthocell appointed Surgical Specialties as exclusive distributor in Australia and New Zealand for Ortho-ATI® and Ortho-ACI® cell therapies for tendon and cartilage regeneration.

Oct 11, 2017